-
C9ORF72 intermediate repeat copies as a rare genetic cause of atypical Parkinsonian syndromes or Parkinson’s disease complicated by psychosis in a Sardinian population
-
CAG repeat length and weight loss in pre-manifest Huntington’s disease
-
CAG repeats number of ATXN7 in SCA7 patients and normal population in Japan
-
Can a leopard changes its spots? How impulse control disorder affects subthalamic stimulation paradigm
-
Can body worn cameras help us understand the complex relationship between physical activity and falls in people with Parkinson’s?
-
Can deep brain stimulation implantation cause multiple system atrophy? A retrospective review of MSA patients
-
Can hospital admissions predict mortality in Parkinson’s?
-
Can intraoperative clinical testing really predict the effects of deep brain stimulation in the subthalamic nucleus?
-
Can quantitative analysis of the “finger-to-nose test” discern between EOA and other conditions of coordination impairment?
-
Can stimulation of deep brain tissue improve the expression of the mouth in Parkinson’s disease patients?
-
Can treadmill training facilitate the dual-task gait in Parkinson’s disease?
-
Cancer comorbidity among PD patients; a population based large-scale cohort study
-
Cancer in Machado Joseph disease patients – Low frequency as a cause of death
-
Cardiometabolic syndrome and risk of Parkinson’s disease: A case-control study in Mexican population
-
Cardiovascular and cerebrovascular disorders are associated with a higher prevalence of parkinsonism: Data from a neuroepidemiologic community-based survey
-
Caring for the majority: Telemedicine management of Parkinson’s disease (PD) in underserved populations in People’s Republic of China: A randomized trial
-
Carrier mediated delivery system bearing dopamine for effective management of parkinsonism
-
Catechol-o-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson’s disease
-
Categories of psychogenic movement disorders to functional blepharospasm
-
Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein
-
Cellular senescence induced by paraquat drives neuropathology associated with Parkinson’s disease
-
Cerebellar ataxia and pregnancy
-
Cerebellar atrophy in Parkinson’s disease and its implication for network connectivity
-
Cerebellar GABA in essential tremor and dystonic tremor: A MR spectroscopy study
-
Cerebellar GABA-A receptor activity is inversely correlated with gait speed in Parkinson’s disease
-
Cerebellar gray matter alterations in Huntington disease: A voxel-based morphometry study
-
Cerebellar learning and its modifiability by alcohol in myoclonus-dystonia
-
Cerebral vasoreactivity in Parkinson’s disease and multiple system atrophy: A pilot study
-
Cerebrospinal fluid biomarkers in Parkinson’s disease and associated cognitive impairment
-
Cervical dystonia and quality of life
-
Cervical dystonia associated to Wallenberg syndrome
-
Cervical dystonia preceding Parkinson´s disease – Continuum – coincidence or epiphenomenon–Report of 3 cases
-
Changes in handwriting following repetitive transcranial magnetic stimulation over pre-motor cortex in Parkinson’s disease
-
Changes in mood and behavior following DBS – Measurement by self-reported questionaires
-
Changes in motor symptoms of Parkinson’s disease: 2-year follow-up of 735 cases
-
Changes in serum amino acid levels with progression of Parkinson’s disease
-
Changes of brain structure and cognition in individuals with possible prodromal Parkinson’s disease
-
Changes of speech after neurostimulation for Parkinson’s disease with early fluctuations: A 2-years randomized controlled trial (earlystim-speech)
-
Characterisation of the A30P mutation in alpha-synuclein gene in patient-derived cellular model of Parkinson’s disease
-
Characteristics of drop outs in a longitudinal study on individuals at risk for a neurodegenerative disorder
-
Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)
-
Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane
-
Characterization and quantitative analysis of prelemniscal radiations in Parkinson´s disease
-
Characterization of burning mouth syndrome in patients with Parkinson’s disease
-
Characterization of European longitudinal cohort studies in Parkinson’s disease – Report of the JPND working group BioLoC-PD
-
Characterization of sleep disturbances in a prospective population-based cohort to investigate Parkinson’s disease
-
Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease
-
Chewing-induced blepharospasm in Parkinson’s disease
-
Children with idiopathic tics reveal additional features of hyperkinetic movement disorders
-
Children with intractable temporal and extratemporal seizures: Correlation of the MR spectroscopy and EEG findings in the surgical planning
-
Chin EMG variance and dream-enactment behavior during polysomnography in Parkinson’s disease
-
Chorea – Ballism drug induced in replacement treatment with thyroid hormones – Case presentation
-
Chorea-acanthocytosis: The first described clinical case in Ukraine
-
Choreoathetosis associated with cervical dystonia as clinical presentation of thyrotoxicosis: A rare condition
-
Chronic acquired hepatocerebral degeneration: Efficacy of liver transplatation in 10 patients
-
Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease
-
Chronic directional subthalamic nucleus deep brain stimulation in Parkinson’s disease – A pilot study
-
Chronic levodopa treatment accelerates the disorders of circadian rhythm in 6-OHDA induced Parkinson’s disease model
-
Ciprofloxacin as the cause of syndroma extrapiramidale
-
Circadian dysfunction in Parkinson’s disease: Effects on impaired gait initiation and locomotion
-
Circulatory levels of BDNF correlate with cognitive deficits in people with Parkinson’s disease
-
Classification and recommendation of nonpharmacological therapies for Parkinson’s disease
-
Clinical and analytical validation of novel autosomal recessive ataxia mutations identified from whole exome sequencing
-
Clinical and behavioral features in carriers of intermediate length alleles of HTT gene. A case series of Mexican population
-
Clinical and biological predictors of excessive daytime sleepiness in early Parkinson’s disease
-
Clinical and biological predictors of time to initiation of symptomatic therapy in early Parkinson’s disease
-
Clinical and genetic analyses in a cohort of the Taiwanese patients with apparently sporadic pure spastic paraplegia
-
Clinical and imaging characteristics of spinocerebellar ataxia type 14 defined in a German multi-center sample
-
Clinical and imaging deterioration of a mild case of Wilson’s disease after chelation therapy
-
Clinical and instrumental features of multiple system atrophy with laryngeal stridor
-
Clinical and instrumental gait analysis study of fear of falling in Parkinson’s disease patients
-
Clinical and molecular features of DYT1 primary dystonia in a Peruvian population
-
Clinical and MRI-characteristics of drug-induced parkinsonism in Uzbekistan
-
Clinical and neuroimaging correlations in early manifest Huntington’s disease patients: Default mode network properties according to resting-state functional MRI
-
Clinical and neuroimaging outcomes up to 18 years after fetal tissue transplant for Parkinson’s disease
-
Clinical and polysomnographic features correlates to sleep-disordered breathing in multiple system atrophy
-
Clinical aspects of postural instability in Parkinson’s disease
-
Clinical benefits of vestibular rehabilitation in neurodegenerative diseases
-
Clinical characteristics and natural history of oromandibular dystonia
-
Clinical characteristics of Parkinson’s disease and essential tremor patients undergoing deep brain stimulation surgery: Five-year data from Columbia University Medical Center (2009 – 2014)
-
Clinical characterization of pramipexole induced edema in Parkinson’s disease (PD). Is it always the best option discontinue the treatment?
-
Clinical correlates of depression and anxiety in patients with Parkinson’s disease
-
Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea
-
Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations
-
Clinical effects of pallidal stimulation in dystonia are quantitatively related to intracortical inhibition
-
Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson’s disease: A prospective study
-
Clinical exome sequencing – diagnostic yield in a sample of German patients with Parkinson’s disease
-
Clinical features of Parkinson’s disease patients developing stridor with acute respiratory failure
-
Clinical outcome of constant current deep brain stimulation in patients with medication-refractory essential tremor
-
Clinical outcome of subthalamic deep brain stimulation in Parkinson’s disease – The Helsinki experience
-
Clinical outcomes of pallidal and subthalamic nucleus deep brain stimulation in isolated cranial and cranio-cervical dystonia
-
Clinical phenotype (motor and neuropsychological presentation) and neuroimaging in Sardinian patients affected by atypical parkinsonisms, carriers of 20-22 repeats of C9ORF72 hexanucleotide expansion
-
Clinical phenotype of Parkinsonian patients with α-synuclein mutation: Our case report and review of the literature
-
Clinical predictors of airway protective dysfunction in Parkinson’s disease
-
Clinical predictors of progressive supranuclear palsy (PSP) pathology in PSP syndrome
-
Clinical presentation and genetic characteristics of Huntingtons disease in Croatia: Thirty years of experience
-
Clinical presentations of 2 Parkin / lysosomal storage disorder heterozygotes with Parkinson’s disease
-
Clinical profile and outcome of hospitalized patients with Parkinson’s disease
-
Clinical profile of Parkinson’s disease at the neurology department of Point G Teaching Hospital
-
Clinical profile of patients with writer’s cramp
-
Clinical profile of Wilson’s disease at Yangon General Hospital, Myanmar
-
Clinically ‘slight’ bradykinesia in Parkinson’s disease is accurately detected using evolutionary computation analysis of finger tapping
-
Clinico-genetic correlation in Indian spinocerebellar ataxia (SCA1) patients
-
Clinicopathological characteristics of co-existant Parkinson’s disease and corticobasal degeneration: A case study
-
Clusterin CSF levels in differential diagnosis of neurodegenerative disorders
-
Co-occurrence of two triplet repeat associated SCA mutations: A dilemma in clinical diagnosis, prognosis and genetic counselling and clinical significance
-
Coding and non-coding glucocerebrosidase variants have an impact on cognitive decline in Parkinson’s disease
-
Cognition and amyloid biomarker status in non-demented patients with Parkinson’s disease patients (PD) with or without subjective cognitive decline (SCD)
-
Cognition, vision and visuo-cognition in gait in Parkinson’s disease
-
Cognitive and behavioral problems in children and adolescents with myoclonus dystonia
-
Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
-
Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT
-
Cognitive and psychiatric outcome 3 years after bilateral deep brain stimulation of the globus pallidus pars interna versus subthalamic nucleus for Parkinson’s disease
-
Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders
-
Cognitive change following deep brain stimulation in patients with movement disorders
-
Cognitive complaint in Parkinson’s disease patients with normal cognition
-
Cognitive decline in Parkinson’s disease: Impact on quality of life of caregivers
-
Cognitive deficits in Parkinson’s disease: A preliminary study of neuropsychological profiles
-
Cognitive development in individuals with mild Parkinsonian signs
-
Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
-
Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
-
Cognitive function and self-reported depressive symptoms in a population-based cohort to study non-motor-symptoms of Parkinson’s disease
-
Cognitive functioning in Parkinson’s disease and Parkinson plus syndrome
-
Cognitive impairment in Huntington’s disease
-
Cognitive impairment in Parkinson’s disease
-
Cognitive impairment in patients with progressive supranuclear palsy and multiple system atrophy
-
Cognitive impairments in children with tic disorders and Tourette syndrome
-
Cognitive outcome in the patients with Parkinson’s disease one year after subthalamic implants in Taiwan
-
Cognitive profile in the Parkinsonian variant of multiple system atrophy: Findings from a Tunisian cohort
-
Cognitive profile of Filipino patients with X-linked dystonia parkinsonism
-
Coin rotation as strongest predictor of buttoning in Parkinson’s: A multicenter study demonstrating the everyday impact of limb-kinetic apraxia
-
Colonic α-synuclein: A potential diagnostic biomarker in Parkinson’s disease
-
Colonic microbiome in Korean patients with Parkinson’s disease
-
Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms
-
Combined effects of visual and auditory cues on gait initiation in Parkinson’s disease
-
Combined imaging markers increase accuracy when predicting real life disease onset in Huntington’s disease
-
Combined pallidal and thalamic stimulation for multifocal primary dystonia with prominent writers’ cramp
-
Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial
-
Communication and language skills in Huntington’s disease
-
Comorbid conditions associated with Parkinson´s disease: A longitudinal study
-
Comorbidity and Parkinson’s disease phenotype, dopaminergic function and CSF biomarkers
-
Comparative analysis of clinical and neuroimaging features of parkinsonism and dementia of Alzheimer’s type
-
Comparative analysis of freezing of gait in distinct parkinsonism types by diffusion tensor imagining and cognitive profiles
-
Comparative analysis of upper limb motor function and articulation disorder in Parkinson’s disease
-
Comparative gait analysis of patients with vascular parkinsonism and idiopathic Parkinson’s disease
-
Comparative study of the substantia nigra echogenicity and 123-I ioflupane SPECT in patients with REM behavior disorder
-
Comparative study patients with different clinical forms of Parkinson’s disease
-
Comparing psychosocial risk factors in patients with functional movement disorders and patients with psychogenic non-epileptic seizures
-
Comparing quality of PD care in a comprehensive clinic to specialist care
-
Comparing the characteristics of patients with Parkinson’s disease speech with and without deep brain stimulation
-
Comparing tremor- and non-tremor effects of ethanol in patients with essential tremor
-
Comparison of change in the UPDRS verses MDS-UPDRS in a population of Parkinson’s disease (PD) patients treated with deep brain stimulation (DBS)
-
Comparison of clinically derived and model based programming parameters of subthalamic nucleus stimulation in Parkinson’s disease
-
Comparison of cognitive and neuropsychological manifestations in patients with progressive supranuclear palsy (Psp) and Parkinson’s disease
-
Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease
-
Comparison of DAT scan, cardiac MIBG scintigraphy, and cerebrospinal fluid 5HIAA levels in Parkinsonian syndrome
-
Comparison of effect of variable deep brain stimulation (DBS) frequencies on gait and balance in Parkinson’s disease (PD) patients with either bilateral GPi or STN stimulators employing wearable wireless sensors
-
Comparison of four DBS lead designs under voltage and current operating modes based on patient specific simulations
-
Comparison of mental practice and proprioceptive neuromuscular facilitation in sisters with cerebellar atrophy
-
Comparison of Test Your Memory (TYM) and Montreal Cognitive Assessment (MoCA) measures in Parkinson’s disease
-
Comparison of the utility of three cognitive scales for MDS Level-I diagnosis of mild cognitive impairment in Parkinson’s disease: MoCA, PD-CRS and ACE-III
-
Comparison of two protocols for neural induction and cultivation of iPSCs derived neural stem cells
-
Compensation strategies for gait in Parkinson’s disease
-
Composite autonomic symptom scale-31 (COMPASS-31) is useful for evaluation of autonomic dysfunction in patients with parkinsonism
-
Comprehensive motor and non-motor staging system in Parkinson’s disease: Results from a global cross-sectional study
-
Computational analysis of expression profiling data in a neuronal model of X-linked dystonia-parkinsonism
-
Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease
-
Computer uses and difficulties in Parkinson’s disease
-
Conjugal Parkinson´s disease – Real or chance?
-
Consolidation of learning and memory in Parkinson’s disease
-
Constant-current stimulation in Parkinson’s disease patients
-
Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers
-
Construct validity of Moca test in a sample of patients with Parkinson´s disease in Bogotá and Cali – Colombia
-
Construction of a levodopa-response index from wearable sensors for quantifying Parkinson’s disease motor functions: Preliminary results
-
Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay
-
Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa
-
Contributions of sensorial feedback to gait in Parkinson’s disease
-
Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
-
Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
-
Coping styles and their influence on outcomes in Parkinson’s disease
-
Copper chelation efficacy of alginate/chitosan based D-penicillamine nanoparticles in rat model of non-Wilsonian brain copper toxicosis
-
Core set of measures of balance for people with multiple sclerosis and cerebellar ataxia
-
Corpus callosum thickness and area in Parkinson’s disease
-
Correlation among DNA methylation status and LINE-1 expression in rat brain
-
Correlation analysis for postural instability and autonomic dysfunction in patients with Parkinson’s disease
-
Correlation between neuro-behavioral symptoms, cognition and gait in patients with dementia with Lewy bodies (DLB)
-
Correlation between Parkinson’s disease and malignant tumors
-
Correlation between self-perceived balance confidence, postural control, gait and quality of life of individuals with Parkinson’s disease
-
Correlation between tremor severity of essential tremor and perpendicular displacement in digital spiral analysis
-
Correlations among motor, cognitive, and neuropsychiatric symptoms in Parkinson’s disease without dementia
-
Cortical and subcortical contribution in the production of reaching movements in Parkinson’s disease
-
Cortical atrophy in cognitively impaired Parkinson’s disease patients
-
Cortical excitability in patients with Parkinson’s disease on levodopa carbidopa intestinal gel thereapy
-
Cortical grey matter atrophy in the motor system in Friedreich ataxia: The IMAGE-FRDA study
-
Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease
-
Cortical phase amplitude coupling (PAC) identifies patterns in clinical states of Parkinson’s disease (PD) using magnetoencephalography (MEG)
-
Cortical role in the freezing of gait in Parkinson’s disease
-
Cortical thinning associated with mild cognitive impairment in Parkinson’s disease
-
Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging
-
Could smell test differ from scans without evidence of dopaminergic deficit and Parkinson’s disease?
-
Could tonic chin electromyogram density be a potential marker for differentiating atypical Parkinsonian syndromes from Parkinson’s disease among alpha-synucleinopathies?
-
Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease
-
Coupling between visual information and body sway in people with Parkinson’s disease
-
Creatine for patients with Parkinson’s disease: A meta-analysis
-
Creative thinking and parkinsonism: Preliminary clinical data on the role of frontal area
-
Creativity related to dopaminergic treatment. A multicenter study
-
Creutzfeldt-Jakob disease presenting predominantly with movement disorder: A case report
-
Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease
-
Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease
-
CSF inflammatory and cell death biomarkers in Huntington’s disease – An exploratory cross-sectional study
-
CSF level of chromogranin A in amyotrophic lateral sclerosis
-
Curcumin supplementation improves motor dysfunction in lipopolysaccharide induced Parkinon’s disease model: Possible biochemical, neurochemical and immunohistochemical alterations in rats
-
Cyclic glycine-proline increased in the cerebrospinal fluid of Parkinson’s patients after supplementation of blackcurrant anthocyanins: Potential biomarker for treatment
-
Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment
2016 International Congress
June 19-23, 2016. Berlin, Germany.